Gene · 2921
NIH grants2,607
NIH grants whose papers are about the gene, through NIH's grant-paper links.
601 to 620 of 2,607
Download this page as JSON| Grant | Title | CXCL3 papers | Newest fiscal year |
|---|---|---|---|
| R01AI152190 | Tickborne SFTS Virus Vaccine Development | 1 | 2024 |
| R01AI153349 | Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging | 1 | 2024 |
| R01AI157155 | Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | 1 | 2024 |
| R01AI161175 | The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodies | 1 | 2024 |
| R01AT010980 | Muscle building supplement HMB for remyelination | 1 | 2024 |
| R01CA172764 | Progression of DCIS to Invasive Breast Cancer through CCR2 Chemokine Signaling | 1 | 2024 |
| R01CA233944 | Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies | 1 | 2024 |
| R01CA236500 | Clinical evaluation of IL13Ra2-targeted CAR T cell therapy in combination with nivolumab in patients with recurrent malignant glioma | 1 | 2024 |
| R01CA238662 | Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662) | 1 | 2024 |
| R01CA239128 | Synthetic lethality based combination approaches to ARID1A mutation in ovarian cancer | 1 | 2024 |
| R01CA239251 | Signaling pathways during hepatocarcinogenesis | 1 | 2024 |
| R01CA240952 | Targeting NQO1+ tumor to trigger innate and adaptive immunity | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA243023 | Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancer | 1 | 2024 |
| R01CA245323 | Mechanisms and therapeutic targets of cancer metastasis | 1 | 2024 |
| R01CA247231 | Targeting defective necroptosis in colorectal cancer | 1 | 2024 |
| R01CA247471 | Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer | 1 | 2024 |
| R01CA248304 | Normalizing arginine metabolism with sepiaptein for immunostimulatory-shift ofHER2+ breast cancer | 1 | 2024 |
| R01CA248493 | Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesis | 1 | 2024 |
| R01CA252937 | Tumor matrix remodeling in anti-myeloma immunity and immunotherapy | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2921/grants?page=31